In this issue:
R2-ISS is a reliable prognostic tool for patients undergoing upfront ASCT
IFM 2018-04: D-KRd plus tandem ASCT promising for high-risk myeloma
The efficacy and safety of tandem versus single transplant
Dismal outcomes for Australian patients with RRMM treated with PBS treatment options
Is D-Rd more efficacious than VRd in transplant-ineligible disease?
T-cell redirecting therapies in triple-class refractory disease
Lower risk of CRS during teclistamab with prior exposure to T-cell redirection therapies
Biomarkers of response to the CAR T-cell therapy ARI0002h for RRMM
Linvoseltamab elicits deep and durable responses in RRMM
Please login below to download this issue (PDF)